Patents by Inventor Onkar N. Singh

Onkar N. Singh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING ON DEMAND SOLID DOSAGE FORMULATIONS
    Publication number: 20210379089
    Abstract: A pharmaceutical composition and methods for using the pharmaceutical composition are disclosed. The pharmaceutical composition may include a therapeutically effective amount of one or more antiviral active pharmaceutical ingredients and a pharmaceutically acceptable excipient. The pharmaceutical composition may be a solid dosage form, wherein the solid dosage form provides sustained release of the antiviral active pharmaceutical ingredient when administered as a vaginal or rectal insert.
    Type: Application
    Filed: October 23, 2019
    Publication date: December 9, 2021
    Inventors: Onkar N. SINGH, Timothy J. MCCORMICK, Vivek AGRAHARI, Melissa PEET, Meredith Roberts CLARK, Jill SCHWARTZ, Gustavo F. DONCEL
  • Sildenafil sublingual spray formulations
    Patent number: 10111833
    Abstract: The invention is directed to sublingual spray formulations containing sildenafil. The invention is further directed to methods of treating male sexual dysfunction or pulmonary arterial hypertension by administering sublingual spray formulations containing sildenafil to patients in need of such treatments.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: October 30, 2018
    Assignee: INSYS DEVELOPMENT COMPANY, INC.
    Inventors: Thrimoorthy Potta, Kiran Amancha, Wesley Giron, Ningxing Yan, Venkat Goskonda, Onkar N. Singh, Holly Redman, Rajesh R Wakaskar
  • SILDENAFIL SUBLINGUAL SPRAY FORMULATIONS
    Publication number: 20170216196
    Abstract: The invention is directed to sublingual spray formulations containing sildenafil. The invention is further directed to methods of treating male sexual dysfunction or pulmonary arterial hypertension by administering sublingual spray formulations containing sildenafil to patients in need of such treatments.
    Type: Application
    Filed: April 17, 2017
    Publication date: August 3, 2017
    Inventors: Thrimoorthy Potta, Kiran Amancha, Wesley Giron, Ningxing Yan, Venkat Goskonda, Onkar N. Singh
  • Sildenafil sublingual spray formulations
    Patent number: 9662334
    Abstract: The invention is directed to sublingual spray formulations containing sildenafil. The invention is further directed to methods of treating male sexual dysfunction or pulmonary arterial hypertension by administering sublingual spray formulations containing sildenafil to patients in need of such treatments.
    Type: Grant
    Filed: April 2, 2016
    Date of Patent: May 30, 2017
    Assignee: INSYS DEVELOPMENT COMPANY, INC.
    Inventors: Thrimoorthy Potta, Kiran Amancha, Wesley Giron, Ningxing Yan, Venkat Goskonda, Onkar N. Singh
  • High Concentration Olopatadine Ophthalmic Composition
    Publication number: 20170071895
    Abstract: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.
    Type: Application
    Filed: November 22, 2016
    Publication date: March 16, 2017
    Inventors: Daniel A. Gamache, Laman Alani, Malay Ghosh, Francisco Javier Galan, Nuria Carreras Perdiguer, Onkar N. Singh
  • High concentration olopatadine ophthalmic composition
    Patent number: 9533053
    Abstract: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: January 3, 2017
    Assignee: Alcon Research, Ltd.
    Inventors: Daniel A. Gamache, Laman Alani, Malay Ghosh, Francisco Javier Galan, Nuria Carreras Perdiguer, Onkar N. Singh
  • SILDENAFIL SUBLINGUAL SPRAY FORMULATIONS
    Publication number: 20160287593
    Abstract: The invention is directed to sublingual spray formulations containing sildenafil. The invention is further directed to methods of treating male sexual dysfunction or pulmonary arterial hypertension by administering sublingual spray formulations containing sildenafil to patients in need of such treatments.
    Type: Application
    Filed: April 2, 2016
    Publication date: October 6, 2016
    Inventors: Thrimoorthy Potta, Kiran Amancha, Wesley Giron, Ningxing Yan, Venkat Goskonda, Onkar N. Singh
  • SUBLINGUAL NALOXONE SPRAY
    Publication number: 20160199294
    Abstract: The invention provides storage stable sublingual formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering the sublingual formulations of the present invention to a patient in need thereof.
    Type: Application
    Filed: March 21, 2016
    Publication date: July 14, 2016
    Inventors: Kiran Amancha, Shivani Chilampalli, Thrimoorthy Potta, Ning Shan, Ningxin Yan, Onkar N. Singh, Venkat R. Goskonda
  • HIGH CONCENTRATION OLOPATADINE OPHTHALMIC COMPOSITION
    Publication number: 20140296328
    Abstract: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.
    Type: Application
    Filed: June 13, 2014
    Publication date: October 2, 2014
    Inventors: Daniel A. Gamache, Laman Alani, Malay Ghosh, Francisco Javier Galan, Nuria Carreras Perdiguer, Onkar N. Singh
  • High concentration olopatadine ophthalmic composition
    Patent number: 8791154
    Abstract: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: July 29, 2014
    Assignee: Alcon Research, Ltd.
    Inventors: Daniel A. Gamache, Laman Alani, Malay Ghosh, Francisco Javier Galán, Núria Carreras Perdiguer, Onkar N. Singh
  • Olopatadine formulations for topical nasal administration
    Patent number: 8399508
    Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: March 19, 2013
    Assignee: Alcon Pharmaceuticals Ltd.
    Inventors: Onkar N. Singh, G. Michael Wall, Rajni Jani, Masood A. Chowhan, Wesley Wehsin Han
  • HIGH CONCENTRATION OLOPATADINE OPHTHALMIC COMPOSITION
    Publication number: 20120295967
    Abstract: The present invention is an ophthalmic composition containing a relatively high concentration of olopatadine. The composition is typically an ophthalmic aqueous solution containing relatively high concentrations of olopatadine solubilized within the solution. The composition is preferably capable of providing enhanced relief from symptoms of ocular allergic conjunctivitis, particularly late phase symptoms of ocular allergic conjunctivitis.
    Type: Application
    Filed: May 18, 2012
    Publication date: November 22, 2012
    Inventors: Daniel A. Gamache, Laman Alani, Malay Ghosh, Francisco Javier Galán, Núria Carreras Perdiguer, Onkar N. Singh
  • Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate
    Patent number: 8173671
    Abstract: Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: May 8, 2012
    Assignee: Alcon Research, Ltd.
    Inventors: Onkar N. Singh, Suresh C. Dixit, Michael Wall
  • OLOPATADINE FORMULATIONS FOR TOPICAL NASAL ADMINISTRATION
    Publication number: 20110306659
    Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.
    Type: Application
    Filed: June 30, 2011
    Publication date: December 15, 2011
    Applicant: Novartis AG
    Inventors: Onkar N. Singh, G. Michael Wall, Rajni Jani, Masood A. Chowhan, Wesley Wehsin Han
  • Olopatadine formulations for topical nasal administration
    Patent number: 7977376
    Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.
    Type: Grant
    Filed: February 7, 2007
    Date of Patent: July 12, 2011
    Assignee: Novartis AG
    Inventors: Onkar N. Singh, G. Michael Wall, Rajni Jani, Masood A. Chowhan, Wesley Wehsin Han
  • Topical Ophthalmic or Otic Solution Formulations Containing Moxifloxacin Hydrocholoride and Dexamethasone Phosphate
    Publication number: 20110082125
    Abstract: Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.
    Type: Application
    Filed: December 14, 2010
    Publication date: April 7, 2011
    Applicant: ALCON RESEARCH, LTD
    Inventors: Onkar N. Singh, Suresh C. Dixit, Michael Wall
  • Topical ophthalmic or otic solution formulations containing moxifloxacin hydrochloride and dexamethasone phosphate
    Patent number: 7888370
    Abstract: Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.
    Type: Grant
    Filed: November 24, 2008
    Date of Patent: February 15, 2011
    Assignee: Alcon Research, Ltd.
    Inventors: Onkar N. Singh, Suresh C. Dixit, Michael Wall
  • TOPICAL OPHTHALMIC OR OTIC SOLUTION FORMULATIONS CONTAINING MOXIFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE PHOSPHATE
    Publication number: 20090137539
    Abstract: Topical ophthalmic and otic solution compositions of moxifloxacin and dexamethasone phosphate are disclosed.
    Type: Application
    Filed: November 24, 2008
    Publication date: May 28, 2009
    Applicant: Alcon Research, Ltd.
    Inventors: Onkar N. Singh, Suresh C. Dixit, Michael Wall
  • Olopatadine formulations for topical administration
    Patent number: 7402609
    Abstract: Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the eye and nose are disclosed. The aqueous formulations contain approximately 0.17-0.62% (w/v) of olopatadine and an amount of polyvinylpyrrolidone or polystyrene sulfonic acid sufficient to enhance the physical stability of the formulations.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: July 22, 2008
    Assignee: Alcon, Inc.
    Inventors: Ernesto J. Castillo, Wesley Wehsin Han, Huixiang Zhang, Haresh G. Bhagat, Onkar N. Singh, Joseph Paul Bullock, Suresh C. Dixit
  • Sustained release ophthalmic, otic and nasal suspension
    Patent number: 7001615
    Abstract: Sustained release suspension formulations for ophthalmic, otic and nasal administration are disclosed. The formulations comprise a basic active, a cation exchange resin, and a combination of a polymeric suspending agents to provide superior resuspendability.
    Type: Grant
    Filed: November 15, 2002
    Date of Patent: February 21, 2006
    Assignee: Alcon, Inc.
    Inventors: Onkar N. Singh, Ernesto J. Castillo